Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

↓

Matched clinical trials

  • Study of 177Lu-FAP-2286 alone and with drug combinations for patients with advanced solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer

    Recruiting

    2 1 1 1
    Belgium France Italy Spain
  • Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

    Recruiting

    3 1 1 1
    Hungary Poland Portugal Romania Spain
  • Study comparing QL2107 and pembrolizumab in patients with resected non-small cell lung cancer receiving adjuvant therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Greece Hungary Poland Romania Spain
  • Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

    Recruiting

    3 1 1 1
    Investigated Drugs:
    Austria Estonia France Germany Ireland Italy +1
  • Safety and feasibility study of fecal microbiota transplant in stage II-III non-small cell lung cancer patients treated with durvalumab, carboplatin, paclitaxel and rifaximin

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Spain
  • Study of zoldonrasib with daraxonrasib, pembrolizumab and chemotherapy in patients with RAS G12D-mutant non-small cell lung cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Austria Czechia Denmark France Germany Greece +3
  • Study of ifinatamab deruxtecan, raludotatug deruxtecan and docetaxel in previously treated stage IV non-small cell lung cancer patients

    Recruiting

    2 1 1 1
    Germany Greece Hungary Italy Poland Spain
  • Study of telisotuzumab adizutecan with osimertinib as first treatment for adults with advanced or metastatic EGFR-mutated non-small cell lung cancer

    Recruiting

    4 1 1 1
    Belgium Italy Portugal Spain
  • Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

    Recruiting

    3 1 1 1
    Belgium France Germany Ireland Italy The Netherlands +2
  • Study of visugromab and nivolumab with or without docetaxel as second-line treatment for patients with metastatic non-squamous non-small cell lung cancer

    Recruiting

    2 1 1
    Germany Italy Poland Romania Spain